advertisement

Topcon

Coleman RA 13

Showing records 1 to 13 | Display all abstracts from Coleman RA

80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodward DF
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Coleman RA; Coleman RA; Woodrooffe AJ; Woodrooffe AJ
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Wang JW; Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Clark KL
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Clark KL
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodrooffe AJ; Woodrooffe AJ
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Toris CB
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Clark KL
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Fan S
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Clark KL; Stamer WD
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277
80215 The affinity, intrinsic activity and selectivity of a structurally novel EP receptor agonist at human prostanoid receptors
Wang JW; Woodward DF
British Journal of Pharmacology 2019; 176: 687-698
80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Tao G; Fan S; Toris CB
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277

Issue 20-3

Change Issue


advertisement

Oculus